Deutsche Bank raised the firm’s price target on Agilon Health to $28 from $26 and keeps a Buy rating on the shares. The company ended 2022 with another solid quarter, reporting a strong sales beat, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGL: